文献速递临床试验与 GCP流行病学与生物统计

利用政策减少慢性阿片类药物使用:TAPERING随机对照试验的研究方案

Leveraging policy to reduce chronic opioid use by educating and empowering community dwelling adults: a study protocol for the TAPERING randomized controlled trial.
PubMed 文献 · Trials · 2019-07-09

本研究为实用型前瞻性整群随机平行对照试验,比较政府主导邮寄患者教育手册与常规护理对社区慢性阿片使用者减药的效果。主要结局为6个月后完全停用阿片类药物,次要结局包括日均吗啡毫克当量剂量降低≥25%、降至<90 mg MME或换药。

要点

  • 政府主导邮寄患者教育材料可能促进慢性阿片使用减量。
  • 主要结局为6个月后完全停用阿片类药物。
  • 整群随机以家庭医学诊所为单元,1:1分配。

核心结论

  • 该试验将评估政府主导的大规模邮寄患者教育能否减少社区成人慢性阿片使用。

研究设计与样本

  • 实用型前瞻性整群随机平行对照试验,在加拿大曼尼托巴省比较邮寄教育手册与常规护理。
  • 由省政府药物计划部门识别合格参与者并分配至初级保健提供者,后者以家庭医学诊所为整群按1:1随机。

关键数值与推荐

  • 主要结局为6个月后完全停用阿片类药物,使用药物计划信息网络数据评估。
  • 次要结局包括日均吗啡毫克当量(MME)剂量降低≥25%、降至<90 mg MME或换用其他阿片或非阿片药物。
  • 采用意向性治疗广义估计方程分析。

临床怎么用

  • 若有效,政府主导的直接面向患者教育邮寄可作为促进慢性阿片减量的群体策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Opioid use has risen to epidemic proportions across Canada, with increasing evidence of harms including accidental overdose and death. Policy-makers have called for effective approaches to promote opioid reduction. One promising method from deprescribing randomized trials is to empower patients through direct-to-patient education. The current trial will evaluate the effectiveness of a government-led mail-out of educational information to adult community-dwelling, chronic opioid users on the reduction of opioids compared to usual care. METHODS: This is a pragmatic, prospective, cluster randomized, parallel-arm controlled trial, comparing mailed distribution of a direct-to-patient educational brochure for chronic opioid use (intervention arm) to usual care (control arm). Eligible participants from across Manitoba, Canada, will be identified by the Provincial Drug Programs Branch within the Manitoba Health, Seniors and Active Living Department of the Manitoba Government, allocated to primary care providers, and the latter will be randomized in clusters of family medicine practices to achieve a 1:1 ratio. The primary outcome is complete cessation of opioids after 6 months assessed using Drug Program Information Network data. Secondary outcomes include ≥ 25% dose reduction in the mean morphine milligram equivalent (MME) daily dose, reduction of daily dose to < 90 mg MME, or therapeutic switch to another opioid or non-opioid medication. Data will be analyzed using intent-to-treat generalized estimating equations. DISCUSSION: This trial will test the efficacy of a population-based, wide-scale, government-led direct-to-patient educational initiative to drive reductions in chronic opioid use by community-dwelling adults across Manitoba. TRIAL REGISTRATION: ClinicalTrials.gov, ID: NCT03400384 . Registered on 18 January 2018.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Turner JP, Caetano P, Tannenbaum C, et al. Leveraging policy to reduce chronic opioid use by educating and empowering community dwelling adults: a study protocol for the TAPERING randomized controlled trial. Trials. 2019. PMID: 31288859. doi:10.1186/s13063-019-3508-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。